conbercept eye drop (KH906)
/ Chengdu Kanghong Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 18, 2026
Pharmacokinetics, safety and preliminary efficacy of conbercept eye drops for corneal neovascularization: Results from phase I/IIa studies.
(PubMed, Br J Clin Pharmacol)
- "KH906 appears safe and well tolerated and demonstrates preliminary efficacy in reducing CorNV, with higher doses showing greater effect, supporting further clinical development."
Journal • P1/2 data • PK/PD data
January 02, 2020
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization
(clinicaltrials.gov)
- P1; N=39; Recruiting; Sponsor: Chengdu Kanghong Biotech Co., Ltd.
Clinical • New P1 trial
1 to 2
Of
2
Go to page
1